Literature DB >> 19124809

Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.

Tobias Klatte1, P Nagesh Rao, Michela de Martino, Jeffrey LaRochelle, Brian Shuch, Nazy Zomorodian, Jonathan Said, Fairooz F Kabbinavar, Arie S Belldegrun, Allan J Pantuck.   

Abstract

PURPOSE: The majority of cytogenetic studies in renal cell carcinoma (RCC) have been impaired by small sample size, retrospective character, and lack of a survival end point. We prospectively studied the prognostic impact of cytogenetic abnormalities on a larger cohort of patients having up to 108 months of follow-up. PATIENTS AND METHODS: Tumors of 282 patients who underwent nephrectomy for clear cell RCC were cytogenetically analyzed. Results were correlated with pathological factors and disease-specific survival.
RESULTS: The most frequently observed cytogenetic abnormalities were loss of 3p (60%), gain of 5q (33%), loss of 14q (28%), trisomy 7 (26%), loss of 8p (20%), loss of 6q (17%), loss of 9p (16%), loss of 4p (13%), and loss of chromosome Y in men (55%). Tumors with loss of 3p presented at lower TNM stages. Loss of 4p, 9p, and 14q were all associated with higher TNM stages, higher grade, and greater tumor size. A deletion of 3p was associated with better prognosis (P = .03), while loss of 4p (P < .001), loss of 9p (P < .01), and loss of 14q (P < .01) were each associated with worse prognosis. Loss of the Y chromosome led to improved progression-free survival in metastatic patients (P = .02). In multivariate analysis, loss of 9p was retained as an independent prognostic factor.
CONCLUSION: This cytogenetic study serves as a proof of principal that genetic information, such as loss of chromosome 9, can be obtained from widely available technology, and can provide additional prognostic information to standard clinicopathologic variables.

Entities:  

Mesh:

Year:  2009        PMID: 19124809     DOI: 10.1200/JCO.2007.15.8345

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  76 in total

1.  Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.

Authors:  Toru Inoue; Keiko Matsuura; Taichiro Yoshimoto; Lam Tung Nguyen; Yoshiyuki Tsukamoto; Chisato Nakada; Naoki Hijiya; Takahiro Narimatsu; Takeo Nomura; Fuminori Sato; Yoji Nagashima; Kenji Kashima; Shingo Hatakeyama; Chikara Ohyama; Kazuyuki Numakura; Tomonori Habuchi; Masayuki Nakagawa; Masao Seto; Hiromitsu Mimata; Masatsugu Moriyama
Journal:  Cancer Sci       Date:  2012-01-20       Impact factor: 6.716

2.  Prognostic and predictive factors in the targeted therapy era: filling in the blanks.

Authors:  Eric Jonasch
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

Review 3.  The role of renal biopsy in small renal masses.

Authors:  Rodolfo Burruni; Benoit Lhermitte; Yannick Cerantola; Thomas Tawadros; Jean-Yves Meuwly; Dominik Berthold; Patrice Jichlinski; Massimo Valerio
Journal:  Can Urol Assoc J       Date:  2016-01-14       Impact factor: 1.862

4.  Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape.

Authors:  Zixing Wang; Tae Beom Kim; Bo Peng; Jose Karam; Chad Creighton; Aron Joon; Fumi Kawakami; Patricia Trevisan; Eric Jonasch; Chi-Wan Chow; Jaime Rodriguez Canales; Pheroze Tamboli; Nizar Tannir; Christopher Wood; Federico Monzon; Keith Baggerly; Marileila Varella-Garcia; Bogdan Czerniak; Ignacio Wistuba; Gordon Mills; Kenna Shaw; Ken Chen; Kanishka Sircar
Journal:  Clin Cancer Res       Date:  2017-07-14       Impact factor: 12.531

5.  Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database.

Authors:  Laura Favazza; Dhananjay A Chitale; Ravi Barod; Craig G Rogers; Shanker Kalyana-Sundaram; Nallasivam Palanisamy; Nilesh S Gupta; Sean R Williamson
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

6.  Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.

Authors:  Yozo Mitsui; Hiroaki Shiina; Taku Kato; Shigekatsu Maekawa; Yutaka Hashimoto; Marisa Shiina; Mitsuho Imai-Sumida; Priyanka Kulkarni; Pritha Dasgupta; Ryan Kenji Wong; Miho Hiraki; Naoko Arichi; Shinichiro Fukuhara; Soichiro Yamamura; Shahana Majid; Sharanjot Saini; Guoren Deng; Rajvir Dahiya; Koichi Nakajima; Yuichiro Tanaka
Journal:  Mol Cancer Res       Date:  2017-02-27       Impact factor: 5.852

7.  Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.

Authors:  Nicole M White-Al Habeeb; Ashley Di Meo; Andreas Scorilas; Fabio Rotondo; Olena Masui; Annetta Seivwright; Manal Gabril; Andrew H A Girgis; Michael A Jewett; George M Yousef
Journal:  Clin Exp Metastasis       Date:  2015-06-03       Impact factor: 5.150

8.  Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.

Authors:  Federico A Monzon; Karla Alvarez; Lief Peterson; Luan Truong; Robert J Amato; Joan Hernandez-McClain; Nizar Tannir; Anil V Parwani; Eric Jonasch
Journal:  Mod Pathol       Date:  2011-07-01       Impact factor: 7.842

9.  Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing.

Authors:  Gabriel G Malouf; Jianping Zhang; Ying Yuan; Eva Compérat; Morgan Rouprêt; Olivier Cussenot; Yunxin Chen; Erika J Thompson; Nizar M Tannir; John N Weinstein; Vicente Valero; David Khayat; Jean-Philippe Spano; Xiaoping Su
Journal:  Mol Oncol       Date:  2014-07-25       Impact factor: 6.603

10.  A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression.

Authors:  Zhongfa Zhang; Bill Wondergem; Karl Dykema
Journal:  Adv Bioinformatics       Date:  2010-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.